Mariette E. Botes

Learn More
y These authors contributed equally to this work and share joint first authorship z See Appendix 1 for institutional affiliations How did the study come about? According to World Health Organization (WHO) estimates , 33.4 million people were infected with the human immunodeficiency virus (HIV) type 1 globally at the end of 2008. 1 Sub-Saharan Africa and(More)
OBJECTIVE Maraviroc, a chemokine co-receptor type 5 (CCR5) antagonist, has demonstrated comparable efficacy and safety to efavirenz, each in combination with zidovudine/lamivudine, over 96 weeks in the Maraviroc vs. Efavirenz Regimens as Initial Therapy (MERIT) study. Here we report 5-year findings. DESIGN A randomized, double-blind, multicenter phase(More)
Donor funds are available for treatment of many diseases such as HIV. However, privacy constraints make it hard for donor organisations to verify that they have not sponsored the same patient twice — or sponsored a patient whose treatment was also sponsored by another donor. This paper presents a protocol based on digital cash that enables donor(More)
  • 1